CHEK1异常剪接驱动U2AF1S34F突变型骨髓增生异常肿瘤中的巨核细胞发育异常
整合MDS患者与U2AF1突变细胞系数据,发现U2AF1突变与巨核细胞发育异常相关,诱导异常巨核细胞(尤其微巨核细胞)生成并导致显著血小板减少。突变U2AF1介导的CHEK1等DNA生物合成相关基因异常剪接是正常巨核细胞多倍体化所必需,CHEK1错剪接导致U2AF1突变MDS患者异常巨核细胞增多;U2AF1S34突变诱导CHK1缺陷及其磷酸化激活,进一步驱动巨核细胞多倍体化与成熟障碍。选择性CHK1抑制剂在体外显著减少异常巨核细胞生成。
要点
- U2AF1突变与巨核细胞发育异常相关,诱导异常巨核细胞(尤其微巨核细胞)生成并导致显著血小板减少。
- 突变U2AF1介导的CHEK1异常剪接是正常巨核细胞多倍体化所必需,其错剪接导致U2AF1突变MDS患者异常巨核细胞增多。
- 选择性CHK1抑制剂在体外显著减少异常巨核细胞生成,提示CHEK1为MDS治疗新潜在靶点。
核心结论
- U2AF1突变通过驱动CHEK1细胞周期相关基因异常剪接诱导异常巨核细胞生成,揭示MDS巨核细胞发育异常的分子基础,并确定MDS治疗的新潜在靶点。
研究设计与样本
- 整合MDS患者与U2AF1突变细胞系数据的研究。
主要发现
- U2AF1突变与巨核细胞发育异常相关,诱导异常巨核细胞(尤其微巨核细胞)生成并导致显著血小板减少。
- 突变U2AF1介导的DNA生物合成相关基因(如CHEK1)异常剪接是正常巨核细胞多倍体化所必需。
- CHEK1错剪接导致U2AF1突变MDS患者异常巨核细胞增多。
- U2AF1S34突变诱导CHK1缺陷及其磷酸化激活,进一步驱动巨核细胞多倍体化与成熟障碍。
- 选择性CHK1抑制剂处理在体外显著减少异常巨核细胞生成。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
U2AF1 mutations are common in patients with myelodysplastic neoplasms (MDS), suggesting that aberrant splicing of pre-mRNAs driven by mutant U2AF1 could play a critical role in MDS pathogenesis. Previous studies have demonstrated that U2AF1S34F mutation impairs the differentiation of erythrocytes and granulocytes, but the impact on megakaryocytes (MKs) remains unclear. Here, by integrating data from MDS patients and cell lines with U2AF1 mutations, we determined that U2AF1 mutations are associated with dysmegakaryopoiesis, induce the generation of abnormal MKs, especially micro-MKs, and induce significant thrombocytopenia. We determined that mutant U2AF1-mediated aberrant splicing of DNA biosynthesis-related genes, such as CHEK1, is required for normal MK polyploidization. The mis-splicing of CHEK1, in turn, accounts for the increased number of abnormal MKs in U2AF1-mutant MDS patients. Moreover, U2AF1S34 mutations induce the deficiency of CHK1 and the activation of its phosphorylation, thereby further driving the impairment of MK polyploidization and maturation. Accordingly, treatment with selective CHK1 inhibitor significantly reduces abnormal MK production in vitro. Taken together, these findings demonstrate that U2AF1 mutations induce the generation of abnormal MKs by driving aberrant splicing of the CHEK1 cell cycle-related gene, revealing the molecular basis for dysmegakaryopoiesis in MDS and identifying a new potential target for MDS treatment.
引用
- Zhang W, Li B, Liu J, et al. Aberrant splicing of CHEK1 is a driver of megakaryocytic dysplasia in U2AF1S34F mutant myelodysplastic neoplasms. Leukemia. 2025. PMID: 40652060. doi:10.1038/s41375-025-02684-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。